logo
Is It Time To Buy AbbVie Stock At $180?

Is It Time To Buy AbbVie Stock At $180?

Forbes16-05-2025
CANADA - 2025/04/03: In this photo illustration, the AbbVie logo is seen displayed on a smartphone ... More screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)
AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This protein is known to promote tumor growth and resistance to certain therapies. This positive news coincides with ABBV's strong stock performance, which has risen nearly 10% in the past six months, notably outperforming the broader S&P Healthcare index, which has declined by 8%.
Contributing significantly to AbbVie's positive trajectory is the exceptional growth within its immunology portfolio, particularly Skyrizi and Rinvoq. These two drugs demonstrated substantial year-over-year growth of 71% and 57%, respectively, in the first quarter of 2025, building upon their impressive 50% growth in the previous year.
While the stock's current high valuation introduces a degree of risk, we maintain a positive outlook on AbbVie. This conclusion is based on a comparative analysis of the company's present valuation against its recent operating performance, as well as its current and historical financial condition. Our assessment across key parameters—Growth, Profitability, Financial Stability, and Downturn Resilience—indicates that AbbVie possesses a strong operating performance and a sound financial condition, as detailed below.
Despite concerns surrounding potential drug price controls, which Wall Street analysts anticipate will likely face legal challenges and be difficult to implement, AbbVie's specific performance appears robust, largely driven by its successful immunology drugs. However, for investors who seek lower volatility than individual stocks, the Trefis High Quality portfolio presents an alternative - having outperformed the S&P 500 and generated returns exceeding 91% since its inception. Separately, see – Is UNH Stock Now A Falling Knife?
Going by what you pay per dollar of sales or profit, ABBV stock looks expensive compared to the broader market.
AbbVie's Revenues have grown marginally over recent years.
AbbVie's profit margins are around the median level for companies in the Trefis coverage universe.
AbbVie's balance sheet looks weak.
ABBV stock has been much more resilient than the benchmark S&P 500 index during some of the recent downturns. While investors have their fingers crossed for a soft landing by the U.S. economy, how bad can things get if there is another recession? Our dashboard How Low Can Stocks Go During A Market Crash captures how key stocks fared during and after the last six market crashes.
In summary, AbbVie's performance across the parameters detailed above are as follows:
In addition: See Buy or Sell AbbVie Stock.
AbbVie's performance, when initially compared to the benchmark S&P 500 index across the aforementioned parameters, appears moderate. However, a closer examination of the adjusted figures reveals a more compelling picture. For example, the company boasts a robust adjusted net income margin of 32%. Furthermore, its price-to-earnings (P/E) ratio, based on adjusted trailing earnings of $10.27 per share, stands at a reasonable 18x.
While this 18x multiple is higher than the stock's three-year average P/E ratio of 14x, we believe this premium is warranted due to the exceptional growth within AbbVie's immunology portfolio. Consequently, we view ABBV stock as a favorable investment at its current levels. Adding to this positive outlook, the average analyst price target of $211 suggests a potential upside of over 15% from the current price.
While ABBV stock looks promising, investing in a single stock can be risky. On the other hand, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Chubb Limited (CB): An Oversold Insurance Giant with a Growing Dividend
Chubb Limited (CB): An Oversold Insurance Giant with a Growing Dividend

Yahoo

timean hour ago

  • Yahoo

Chubb Limited (CB): An Oversold Insurance Giant with a Growing Dividend

Chubb Limited (NYSE:CB) is included among the 10 Oversold Dividend Stocks to Buy According to Hedge Funds. A close-up of an insurance agent's hand pointing to a marine insurance policy, highlighting the company's expertise in marine coverage. Chubb Limited (NYSE:CB) ranks among the largest publicly traded property and casualty insurers in the world. In recent years, the company has worked to grow its presence outside of North America, with particular focus on markets in Asia, Latin America, and Europe. Its strategy centers on disciplined underwriting, meaning it takes a careful approach to selecting which risks to insure and how to price them, while also aiming to manage risk across multiple product lines and regions. In the second quarter of 2025, Chubb Limited (NYSE:CB) reported P&C net premiums written of $12.39 billion, which showed a 5.2% growth from the same period last year. Net income rose to $2.97 billion, marking an increase of 33.1%, while core operating income reached a record high of $2.48 billion, reflecting a 12.9% gain. Property and casualty underwriting income reached a record $1.63 billion, representing a 15.0% increase, while the combined ratio stood at 85.6%. Chubb Limited (NYSE:CB)'s cash position also remained stable during the quarter. The company's operating cash flow came in at $3.55 billion and ended the quarter with cash and cash equivalents of $2.4 billion. During the quarter, the company also returned $388 million to shareholders through dividends. In addition, it holds a 32-year streak of consistent dividend growth. The company offers a quarterly dividend of $0.97 per share and has a dividend yield of 1.44%, as of July 25. While we acknowledge the potential of CB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity
Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity

Yahoo

timean hour ago

  • Yahoo

Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity

Abbott Laboratories (NYSE:ABT) is included among the 10 Oversold Dividend Stocks to Buy According to Hedge Funds. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% growth on a YoY basis. The company reported GAAP diluted earnings per share of $1.01, while adjusted diluted EPS came in at $1.26. Gross margin was 52.7% of sales on a reported basis, with the adjusted gross margin reaching 57.0%, representing a 100 basis point improvement. Abbott Laboratories (NYSE:ABT) reiterated its guidance and pointed to strong momentum in both its devices and nutrition segments as it moves into the second half of the year. A brief valuation analysis, based on a five-year free cash flow CAGR of 5.74%— calculated using 6% growth in operating cash flow and 2% growth in capital expenditures— suggests that the current share price of $120.51 offers promising return potential. On June 13, Abbott Laboratories (NYSE:ABT) declared a quarterly dividend of $0.59 per share, which was in line with its previous dividend. This was the company's 406th consecutive quarterly dividend. In addition, ABT has raised its payouts for 53 years in a row. The stock offers a quarterly dividend of 1.86%, as of July 25. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity
Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity

Yahoo

timean hour ago

  • Yahoo

Oversold Abbott Laboratories (ABT) Could Offer a Healthy Dividend Opportunity

Abbott Laboratories (NYSE:ABT) is included among the 10 Oversold Dividend Stocks to Buy According to Hedge Funds. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% growth on a YoY basis. The company reported GAAP diluted earnings per share of $1.01, while adjusted diluted EPS came in at $1.26. Gross margin was 52.7% of sales on a reported basis, with the adjusted gross margin reaching 57.0%, representing a 100 basis point improvement. Abbott Laboratories (NYSE:ABT) reiterated its guidance and pointed to strong momentum in both its devices and nutrition segments as it moves into the second half of the year. A brief valuation analysis, based on a five-year free cash flow CAGR of 5.74%— calculated using 6% growth in operating cash flow and 2% growth in capital expenditures— suggests that the current share price of $120.51 offers promising return potential. On June 13, Abbott Laboratories (NYSE:ABT) declared a quarterly dividend of $0.59 per share, which was in line with its previous dividend. This was the company's 406th consecutive quarterly dividend. In addition, ABT has raised its payouts for 53 years in a row. The stock offers a quarterly dividend of 1.86%, as of July 25. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store